-
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare disease company with a presence in Philadelphia
20 Dec 2025 02:33 GMT
… companies announced Friday.
The acquisition of Amicus, expected to … Why Philadelphia loses promising biotech firms to Boston, San … spinoff, according to Fierce Biotech.
The University of … of the Biotechnology Innovation Organization (BIO), a biotech trade …
-
Patent cliffhanger: will China biotech throw Big Pharma a lifeline?
20 Dec 2025 00:14 GMT
If pharmaceutical drug patents are an hourglass turned over on the day of approval – with the approaching loss of exclusivity known in the industry as the “patent cliff” – then Big Pharma is currently watching the final grains of sand slipping through the …
-
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
19 Dec 2025 22:05 GMT
… ”) (the “Continuance”) and the subsequent acquisition by HS North America Ltd … Inc. is a clinical-stage biotechnology company committed to developing precision … risk that competing offers or acquisition proposals will be made; the …
-
Sam Altman Launches Merge Labs: Non-Invasive BCI Rival to Neuralink
19 Dec 2025 20:48 GMT
… Merge Labs from Forest Neurotech highlights a growing trend in biotech … in Merge Labs extends his influence across AI, biotech, and … public discourse could shape Merge’s communication strategy, emphasizing … a precedent for future biotech ventures. As Altman …
-
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
19 Dec 2025 20:11 GMT
… Friday is the second acquisition for BioMarin under CEO … San Rafael, California-based biotech currently markets five such … deficiency Pompe disease. The biotech’s first commercialized product … D pipeline.
The Amicus acquisition is expected to immediately …
-
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
19 Dec 2025 16:00 GMT
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully …
-
ProPhase Labs announces LOI for reverse merger with Advanced Biological
19 Dec 2025 15:12 GMT
… reverse merger transaction with Advanced Biological Laboratories (ABL), a European biotechnology and …
-
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
19 Dec 2025 12:00 GMT
… regarding a proposed reverse merger transaction pursuant to which … be separate from the merged operating company. Additionally, … obligations of the post-merger entity. Transaction Status … a European MedTech and biotechnology group providing integrated solutions …
-
Advanced Biological Laboratories Signs Non-Binding LOI for Proposed Reverse Merger with ProPhase Labs
19 Dec 2025 07:00 GMT
… a proposed reverse merger transaction pursuant to which … be separate from the merged operating company. Additionally, … obligations of the post-merger entity.
Transaction Status
… a European MedTech and biotechnology group providing integrated solutions …
-
Top 10 Advanced Biotech Firms In 2026
18 Dec 2025 20:04 GMT
… Pharmaceuticals has achieved what few biotechnology companies accomplish: transforming the treatment … into protein analysis through its acquisition of SomaLogic for four hundred … approaches.
The company’s strategic merger with Exscientia in 2024 significantly …
About
© 1995-2025